老年人严重抑郁症的药物治疗:从一个基于证据的逐步算法到精准医学
Eric J Lenze1, Jordan F Karp2, Marie Anne Gebara3
1Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA. lenzee@wustl.edu.
概括
这项研究提出了一种逐步的算法,用于治疗老年人的晚期抑郁症 (LLD),优先考虑安全性和有效性. 它还探讨了用于个性化抑郁症治疗的精准医学方法.
科学领域:
- 老年学是一门学科.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚年抑郁症 (LLD) 在老年人中存在独特的临床复杂性,原因是多病症,脆弱性和多药性.
- 由于添加或更改中枢神经系统活性药物的风险增加,管理LLD具有挑战性.
- 越来越多的抗抑郁药选择需要谨慎的风险效益平衡,以有效的LLD治疗.
研究的目的:
- 提出一个基于证据的,逐步算法,用于晚年抑郁症的药物治疗.
- 概述LLD的治疗升级策略,包括药物切换,增强和替代疗法.
- 讨论新兴的精准医学方法,以优化LLD治疗结果.
主要方法:
- 基于三十年临床试验数据的逐步治疗算法的开发.
- 顺序的药物治疗建议从SSRI开始,然后是SNRIs,以及增强策略.
- 包括非药物治疗,如心理治疗,TMS,胺和ECT,用于耐火病例.
主要成果:
- 拟议的算法优先考虑选择性血清素再吸收抑制剂 (SSRI),因为它们的安全性和易用性.
- 治疗升级包括切换到血清素 - 上腺素再吸收抑制剂 (SNRIs) 或增加像阿里皮普拉这样的药物.
- 对于对传统药物治疗不反应或不耐受的患者,建议使用TMS,胺和ECT等替代疗法.
结论:
- 逐步算法旨在最大限度地提高LLD药物治疗的有效性,并最大限度地降低LLD药物治疗的风险.
- 精准医学方法,包括生物类型和区分简单与复杂的抑郁症,对未来的LLD治疗有希望.
- 这些策略预计将改善日益增长的抑郁症老年人群的结果.
更多相关视频
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
1.8K
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
743
相关概念视频
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
01:23Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
01:15Drug Dosing: Geriatric Patients
392
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
392
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
377
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
377
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
393
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
393
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
365
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
365